

# Integrative Medicine Approaches to Gluten Sensitivities

Christina Rahm\*, M.S., Ph.D., Ed.D.

USA

Corresponding Author: Christina Rahm, M.S., Ph.D., USA.

Received: 📅 2024 Oct 01

Accepted: 📅 2024 Nov 22

Published: 📅 2025 Jan 28

## 1. Introduction

With the popularization of gluten-free diets and growing medical recognition of non-celiac gluten reactivity, research interest has expanded substantially in recent years, seeking to advance scientific understanding and clinical management approaches for those exhibiting negative responses to gluten in the absence of celiac disease or wheat allergy [1]. Yet, the protean clinical manifestations, lack of confirmatory biomarkers, and reliance on non-standardized gluten challenge procedures currently limit optimal care amid this likely underdiagnosed and undertreated patient group [1]. Hence, by comprehensively synthesizing insights from immunological, neurological, psych behavioral, nutritional, and patient-outcomes research perspectives through a systematic review of the accumulating evidence base, this analysis clarifies contemporary scientific knowledge related to contributory mechanisms, clinical evaluations, therapy considerations, lingering critical unknowns, and emerging areas ripe for impactful study across the domains of basic science as well as diagnostic and therapeutic innovation [2]. It aims to propose an integrated future research agenda encompassing both reductionist and holistic investigative paths towards the shared goal of illuminating definitive causal explanations, cost-effective precision diagnostics, evidence-guided lifestyle-based management recommendations, and compassion-driven support resources necessary to alleviate the substantial yet often unaddressed burdens associated with fundamental food intolerance towards enhancing well-being and promoting dignity for all contending with non-celiac gluten sensitivity well into the twenty-first century and beyond.

### 1.1. Literature Review

#### 1.1.1. Epidemiology of Gluten Sensitivity

Non-celiac gluten sensitivity (NCGS) is more common than we initially thought. Early research state that 0.6-6 % of people have gluten sensitivity [3]. But newer studies are showing higher rates, with 3-13% of people in different countries reporting gluten issues [3]. So, it affects people of all ages, which is good to know. The exciting thing is that way more women tend to have problems with gluten than men. The split can be as high as 5 women to every 1 man [2]. Makes you wonder why. Based on research so far, it might have something to do with differences in gut bacteria between men and women or with female hormones like

estrogen playing a role in reacting to gluten [4]. More studies are needed to understand better.

Also, it looks like a good chunk of people who go gluten-free between 17-30% do it because they feel better without gluten, even if they haven't been officially diagnosed with celiac disease [2,3]. So, it seems like there are probably more people out there dealing with gluten sensitivity than we capture through diagnoses alone. This tells me we need to get better at recognizing symptoms and helping people figure out if gluten is a problem for them or not. Moreover, non-biological factors like women's heightened awareness of their medical conditions may lead to better reporting rates and openness about personal health matters [4]. Whatever reason for the substantial disparity between men and women necessitates further research into the relationships between gender-specific variables and NCGS growth and appearance.

Although initial studies concentrated on populations of European lineage, new evidence suggests NCGS may affect people of all ethnicities [2]. For example, despite lower captured celiac disease diagnoses in these geographic areas, studies among cohorts from South America, Africa, and Asia show significant gluten sensitivity rates and gluten-free diet compliance [5]. More detailed analysis within diverse populations would yield valuable global NCGS epidemiological information, even though differences may reflect differences between the intrinsic immune response to gluten versus adaptive autoimmune responses [2]. Comprehending the possible hereditary and cultural factors that impact susceptibility may facilitate customized diagnostic and therapeutic strategies that consider patients' backgrounds in society.

#### 1.1.2. Presentation of Gluten Sensitivity

A defining feature of NCGS is the onset of intestinal and extraintestinal symptoms triggered by gluten ingestion [6]. Gastrointestinal symptoms resemble irritable bowel syndrome, encompassing diarrhea, abdominal pain, bloating, and nausea [2]. Extraintestinal manifestations vary widely, including neurological symptoms like headaches, "brain fog," anxiety, depression, fatigue, joint pain, and numbness [2]. A subset of patients also presents with eczema, rhinitis, asthma, or anemia [6]. Symptoms emerge hours to days following gluten consumption and can persist if gluten

intake continues [2]. The variability and non-specific nature pose challenges for differentiation from other gluten-related disorders.

While abdominal discomfort represents the most common complaint, systemic symptoms are reported in 35-66% of NCGS patients and can overshadow or occur in isolation from gastrointestinal upset [2]. Bloating constitutes the predominant gastrointestinal sign across adults and children with 74-91% rates, followed by abdominal pain, nausea, aerophagia, and gastroesophageal reflux [2]. Among neurological manifestations, foggy mind or headaches arise most prominently with frequencies of 14-57%, distantly trailed by mood disturbances, fatigue, limb numbness, ataxia, and hallucinations occasionally documented [2]. Up to 40% experience multiple concurrent extraintestinal sequelae spanning cutaneous, respiratory, musculoskeletal, hematologic, and another organ involvement [7]. While patient demographics like age and sex influence specific symptom profiles, multifaceted system-wide presentations reinforce viewing NCGS as a complex multi-organ sensitivity disorder.

From the case study on gluten sensitivity presented earlier, the 38-year-old female patient exhibited clinical manifestations aligning with common NCGS symptomology [8]. Her recurring gastrointestinal distress upon wheat and gluten ingestion, improved by a gluten-free diet, reflects presentation documented in broader NCGS cohorts [2]. While celiac disease was excluded through diagnostic testing, her symptoms substantiate previous reports on autoinflammatory activation potentially instigated by gluten components in NCGS pathophysiology [9].

### 1.1.3. Pathophysiological Mechanisms

While the precise pathophysiological processes remain ambiguous, evidence implicates innate immune system activation, epithelial barrier dysfunction, and dysbiotic changes as contributors to NCGS [9]. Elevated levels of toll-like receptor 2 signaling molecules and heightened intestinal permeability suggest gluten peptides may trigger inflammatory pathways by escaping intestinal barriers [9]. Alterations in intestinal microbiota, increased IGA anti-gliadin antibodies, and cytokine involvement also indicate some degree of immune activation akin to, but less pronounced than, celiac disease [7,9]. Additionally, carbohydrates like fructans abundant in wheat products have demonstrated the capability to induce gastrointestinal symptoms reminiscent of NCGS, suggesting FODMAP malabsorption may play a secondary role [2]. Further research is essential to clarify mechanisms and discern components eliciting reactions.

Immune theories posit that analogous to celiac disease, selective gluten peptides traverse compromised epithelial junctions to interact with antigen-presenting cells, prompting cytokine release by intraepithelial lymphocytes (Professional, C. C. medical, n.d.). Subsequent recruitment of lymphocytes and macrophages cultivates intestinal mucosal and systemic inflammation (Professional, C. C. medical, n.d.). Alternatively, according to the stress-induced epithelial

pathway premise, physiological stressors disrupt epithelial tight junctions, enabling hyperpermeability and permitting gluten access to submucosal regions [10]. Ensuing immune stimulation by other microbiota antigens or luminal contents spurs inflammation [10]. Each postulate provides plausible initial steps destabilizing homeostasis upon non-celiac gluten ingestion, though explicitly implicates different primary triggering antigens.

Beyond immunological reactions, the microbiome represents another mediator theorized to elicit and exacerbate NCGS manifestations independently and secondarily. Compelling evidence shows wheat components, including gluten proteins and amylose-trypsin inhibitors, directly activate innate immune receptors like toll-like receptor 4 or nucleotide oligomerization domains stimulating proinflammatory signaling [11]. Furthermore, like models in inflammatory bowel disease, gluten-induced malabsorption and changes in the intestinal barrier may modify microbiota, allowing aggressive bacteria to proliferate and trigger additional immune responses [12]. According to Junker (2012) dysbiosis may also cause gastrointestinal distress by accelerating the fermentation of carbohydrates and gas production [11].

Furthermore, considering microbiome transfer experiments in germ-free mice confirm the ability for NCGS phenotype induction, microbiota populations likely serve pivotal NCGS functions beyond compounding intestinal damage [11]. Ultimately, given their potential to work in concert to intensify inflammation, understanding the relationship between intestinal barrier integrity dysfunction, stress, and gluten sensitivity is still crucial. Psychosocial stress notoriously disrupts gut epithelial tight junctions by releasing corticotropin-releasing factor, substance P neurotransmitters, and mast cell activation pathways [13]. Localized and systemic immune responses are triggered by the secondary translocation of food antigens and microbiota [13]. Meanwhile, direct infection studies confirm specific gliadin peptides prompt enterocyte apoptosis and degrade transmembrane junctions [8]. Hence, in gluten-sensitive individuals, the combined influence of gluten oligopeptides and psychological stress factors enabling their transport may substantially amplify reactions. Stress management could dually dampen baseline intestinal hyperpermeability and reactivity to episodic gluten exposures.

From the case study on gluten sensitivity presented earlier, the 38-year-old female patient exhibited clinical manifestations aligning with common NCGS symptomology [8]. Her recurring gastrointestinal distress upon wheat and gluten ingestion, improved by a gluten-free diet, reflects presentation documented in broader NCGS cohorts [2]. While celiac disease was excluded through diagnostic testing, her symptoms substantiate previous reports on autoinflammatory activation potentially instigated by gluten components in NCGS pathophysiology [9].

### 1.1.4. Diagnosis of Gluten Sensitivity

No biomarker or laboratory test definitively diagnoses

NCGS [2]. Instead, diagnosis relies upon symptomatic assessment, exclusion of alternative etiologies through extensive testing, and gluten withdrawal and rechallenge trials [14]. Patients undergo a minimum 6-week gluten-free diet and monitor for symptom changes before methodically reintroducing gluten to confirm the causative relationship [14]. This process underpins the diagnostic protocol in the case study, substantiating the efficacy of a stepwise elimination approach to identify gluten sensitivity [14]. Blind placebocontrolled trials are the gold standard, though they are rarely implemented in routine clinical practice [14]. Refining biomarkers and diagnostic techniques is paramount for enabling earlier diagnosis and treatment.

Excluding confounding disorders with overlapping gastrointestinal symptoms like inflammatory bowel disease, microscopic colitis, pancreatic insufficiency, small intestinal bacterial overgrowth, and lactose intolerance remains imperative before confirming NCGS [2]. Evaluating for extraintestinal conditions, including iron deficiency anemia, IgE-mediated wheat allergy, and psychiatric disorders, also helps characterize the clinical picture [9]. As showcased in the case report, initial bloodwork ruled out celiac disease, and iron studies together with systematic diet trials facilitated isolating gluten as the inciting culprit among other secondary causes like irritable bowel syndrome frequently cooccurring with NCGS [14].

No serological, genetic, histological, or fecal markers conclusively identify NCGS [9]. Up to 50% of patients demonstrate positive IgA or IgG anti-gliadin antibodies, 20% display antinuclear antibodies, and about 15% exhibit anti-enterocyte IgA or IgG antibodies; however, none prove specific or adequately sensitive for diagnosis [2]. Elevated fecal eosinophil cationic protein, interleukin-8, and interferon-gamma levels signal unspecified intestinal inflammation [7]. DQ2 and DQ8 haplotypes occur regularly, though rates equal general population frequencies [2]. Histopathological changes generally remain unremarkable or negligible aside from occasional lymphocytic infiltration [7]. Hence, blinded gluten challenge combining metastable symptom monitoring and systematic reintroduction is the primary diagnostic technique for confirming causality.

### 1.1.5. Treatment Approaches

A strict gluten-free diet constitutes the cornerstone treatment for NCGS, with most patients exhibiting symptom control when adherence is maintained [9]. Eliminating grains containing gluten proteins like wheat, barley, and rye can significantly improve gastrointestinal and systemic manifestations [6,9]. Accordingly, the case study patient demonstrated marked amelioration of symptoms through adhering to a gluten-free diet [14]. Additional patients report improved wellbeing with concurrent probiotic and prebiotic regimens to counterbalance intestinal microbiota disruption [14]. Though still investigational, certain dietary supplements, including digestive enzymes like prolyl endopeptidase, have exhibited the capacity to degrade immunotoxic gluten peptides and warrant further research [14]. Ultimately, multi-dimensional lifestyle changes, not

pharmaceuticals, currently serve as frontline approaches for NCGS.

Eliminating gluten necessitates vigilance in navigating trace exposures in processed foods, condiments, and supplements with precise inspection of labels denoting the presence of wheat, rye, and barley ingredients [6]. Given the ubiquity of gluten-containing additives, patients should receive detailed education by expert dietitians to identify overt and hidden sources. One way to diversify nutritional intake and avoid restrictive eating is to use naturally gluten-free ancient grains such as rice, corn, millet, and amaranth as a wheat substitute [6]. The effectiveness of commercial gluten detection products in detecting contamination has been the subject of conflicting research [6]. Although these orientations are beneficial for recently diagnosed patients, they shouldn't take the place of carefully reading labels and being aware of familiar places where gluten can be hidden, such as soy sauce, because deficiencies have been found that make it challenging to identify specific sources of gluten.

There is ongoing discussion regarding the necessity of removing all grains, regardless of their innate gluten content. Permitting gluten-free grains could, on the one hand, maintain fiber consumption and diversify choices in contrast to extreme restriction [9]. On the other hand, even in the absence of gluten, overlapping biological compounds in grains may worsen symptoms; these can be better managed with expansive limitation [9]. The effectiveness of global exclusion diets has been supported by a blinded trial involving non-celiac IBS cohorts, which found that gluten- and gluten- and grain-free diets improved gastrointestinal symptoms more than placebos [9]. As individuals who resist change, an indefinite multigrain eradication plan and a phased reintroduction of particular grains could help determine the optimal sustainable dietary composition.

Adjunctive therapies like probiotics, prebiotics, and digestive enzymes aim to lessen the adverse effects of gluten reactions by restoring eubiosis, preserving the integrity of the intestinal barrier, and accelerating the digestion of gluten [9]. Several probiotic randomized control trials utilizing various genera and strains—including *Bifidobacterium infantis*—have demonstrated a particular efficacy in mitigating the symptoms of noncommunicable gastrointestinal syndrome (NCGS), such as bloating, altered stool consistency and abdominal pain, by Junker [11]. Specific *Lactobacillus Getting Ready* and *Saccharomyces boulardii* also show quantifiable advantages [11]. Though probiotic species and protocols warrant further optimization, certain products promise to mitigate complications like microbiota disruption in gluten-sensitive cohorts.

Another novel strategy to promote helpful microbial species like *Bifidobacterium* is prebiotic supplementation with the hormone insulin and galactooligosaccharides [11]. More thorough, rigorous studies of prebiotic regimens are still required to support preliminary findings, even though small trials can potentially restore inflammatory parameters and improve manifesting symptoms [11]. Likewise, for

digestive enzymes, early reports demonstrate that gluten-degrading preparations containing prolyl endopeptidases can ameliorate enteropathy and manifestations in celiac disease, laying the foundation for expanded NCGS research [15]. Hence, scientists posit sensible future protocols should evaluate integrated symbiotic formulations pairing selected probiotics and prebiotics with enzymatic activity to holistically transform gluten metabolism and microbiome landscapes [15].

Beyond nutritional intervention, incorporating stress-reduction practices and physical activity bears consideration in mitigating systemic NCGS symptoms related to inflammation [6,9]. As the case study protocol highlights, yoga, meditation, breathing exercises, exercise routines, and prioritizing adequate sleep could supplement gluten-free dietary changes [8]. Though clinical studies directly assessing such holistic complementary approaches for NCGS are lacking, their emerging promise for related gastrointestinal conditions indicates potential areas for investigation [8].

### 1.1.6. Prognosis and Long-Term Consequences

While gluten withdrawal commonly induces swift improvements, strict lifelong adherence is often necessary to sustain resolutions of chronic symptoms or inflammation [6]. Lapses in compliance or trace gluten exposures can precipitate relapse in some NCGS patients [6]. However, interestingly, a subset of individuals appears capable of tolerating occasional gluten meals or can revert to regular diets after a period of gluten restriction with no recurrence of adverse reactions [6]. More research into prognostic outcomes could enlighten whether NCGS represents a completely irreversible condition or an interim gluten hypersensitivity.

Associations between NCGS and subsequent autoimmune disease development remain uncertain. Some posit early treatment of NCGS may obstruct the triggering of additional gluten-related disorders over time [7]. One study detected an increased likelihood of NCGS patients testing positive for anti-gliadin antibodies later in life compared to non-NCGS controls, suggesting escalating immunoreactivity (Volta, Caio, Stanghellini, De Giorgio, 2014). However, more extensive longitudinal studies tracking long-term antibody and symptom changes are needed to further investigate relationships between gluten sensitivity states. While strict dieting often successfully controls acute reactions, nutritional adequacy over decades merits assessment given restrictive eating risks. Cross-sectional surveys reveal that 35-45% of adults on gluten-free diets exhibit some form of nutritional deficiency or imbalance, including inadequate fiber, vitamin D, calcium, iron, zinc, magnesium, folate, or omega-3 fatty acids [16].

### 1.1.7. Quality of Life and Psychological Functioning

Beyond physical distress, NCGS imparts substantial psychosocial and emotional burdens for affected individuals. Qualitative reports detail adverse impacts on daily functioning, the ability to dine out with friends, and strictly monitoring one's diet [8]. Quantitatively, patients

describe impaired vitality and social functioning using standardized quality-of-life scales [8]. Feelings of isolation, embarrassment, guilt, anger, and frustration represent additional complex psychological challenges conveyed by those adhering to gluten-free diets, with some even meeting the criteria for depression [8].

While the case study showed quality of life improvement and work functioning enhancement after symptom cessation, long-term, rigid dietary restrictions pose ongoing psychological challenges warranting support [8]. Optimal management should encompass holistic measurement of patient well-being using validated mental health screening tools coupled with multidisciplinary collaboration between gastroenterologists, psychiatrists, therapists, and dietitians.

Beyond negative emotions, tangible lifestyle constraints accompany therapeutic dieting. Vigilance inspecting ingredient labels, calling ahead to vet restaurant menus, traveling with custom food, and disclosing diets to avoid social offense manifest as daily hindrances [17]. Comparatively lower health-related quality of life measures across mental and physical domains in non-celiac gluten sensitivity versus celiac disease patients further capture profound lifestyle sacrifices [18]. A widespread dissatisfaction and feelings of deprivation may be countered by practicing mindfulness that promotes adoption, self-compassion encouragement, and support groups to exchange advice on managing obstacles [17].

### 1.1.8. Diagnostic and Treatment Limitations in Routine Clinical Practice

Patients are becoming more aware of NCGS, but doctors' constraints in their day-to-day work prevent prompt detection and treatment. The inability to identify NCGS from a wide range of differential diagnoses is impeded by the need for a valid biomarker [2]. This issue worsens because healthcare providers and other specialists, besides gastroenterologists, need to be more knowledgeable about acceptable diagnostic protocols and trained in organized elimination procedures [2]. Once diagnosed, optimal dietary guidance is hampered by limited access to dietitians skilled in gluten-free nutrition planning [2]. Patients face additional challenges due to financial constraints that limit their access to more expensive specialized gluten-free nourishment [2]. These shortcomings showcase the need for augmented NCGS education and resource allocation to support frontline providers and vulnerable patients.

In surveys assessing provider knowledge, under 50% of physicians expressed confidence in recognizing hallmark NCGS symptoms or distinguishing the condition from celiac disease and wheat allergy [19]. Fewer than 25% regularly applied accurate elimination diets and gluten challenges for diagnosis; instead, they primarily relied upon serological testing that needed more sensitivity and specificity [19]. Gastroenterologists exhibited the most significant diagnostic competency, expected given specialized exposure, though even average scores on knowledge assessments barely surpassed 60% correct [19]. Efforts to boost access to



continuing medical education focusing on NCGS and promote advanced training opportunities remain vital to uplift diagnostic skills, particularly among primary care providers and allied health fields interacting with undifferentiated early presentations.

## 1.2. Future Research Directions

### 1.2.1. Elucidating Definitive Pathophysiological Mechanisms

While associations have been established between gluten ingestion and symptom provocation in NCGS, the precise pathways underpinning this relationship remain unclear [20]. Proposed mechanisms, including immune activation, small intestinal barrier changes, gluten opioid activity, and microbiome-mediated effects, warrant further elucidation through randomized controlled trials (RCTs) incorporating marker measurement and structured gluten challenges [20]. Delineating contributory processes could enhance diagnostic accuracy, inform therapeutic targets beyond gluten avoidance, and identify monitoring metrics gauging management effectiveness.

### 1.2.2. Identifying Diagnostic Biomarkers

The absence of confirmatory serological, genetic, or histological features hampers NCGS diagnosis, necessitating the exclusion of alternate etiologies in symptomatic patients responding to gluten withdrawal [2]. Efforts to discover reliable biomarkers could significantly advance diagnostic capabilities. Analyzing patients with blinded gluten challenges versus controls may reveal immunological, genetic, metabolic, or gastrointestinal markers distinguishing confirmed gluten reactivity. Once verified through additional RCTs, these lab-based or point-of-care diagnostics could revolutionize clinical evaluation and monitoring [2].

### 1.2.3. Developing Gold Standard Challenge Procedures

Despite recognizing the utility of gluten challenges in diagnosing NCGS, more consensus is needed regarding optimal methodological approaches. Areas requiring clarification include Challenge duration and intervals. Both short (days) and prolonged (weeks) regimens have been incorporated, but comparisons within individual patients still need to be made [21]. Randomization and blinding protocols. While ideal for minimizing bias, deception methods warrant further ethical consideration [21]. Gluten dosage and formulation. Elevating doses or observing responses to different gluten sources could enhance detection sensitivity [21]. Concurrent elimination diets. Whether co-eliminating other grains or foods during challenges confers added specificity requires investigation [21].

Standardizing evidence-based challenge protocols could assist diagnosticians worldwide in reliably applying this invaluable assessment tool. Testing newly developed digestive enzymes that break down gluten new enzymes that break down gluten are promising experimental treatments that may allow for more diet liberalization options than strictly avoiding gluten.

Items that are presently in the early stages of testing include:

- AN-PEP: cysteine endoprotease from germinating barley seeds [22].
- STAN1: bacterial prolyl endopeptidase from *Flavobacterium* [23].
- Prolyl endoprotease from *Geobacillus stearothermophilus*, a non-pathogenic bacterium, is BL-7010 [24].

As stand-alone or adjunctive treatments, these new-generation enzymes may help further individualize medical and nutritional approaches for individuals with demonstrable gluten reactivity if they are effective without causing significant adverse effects.

### 1.2.4. Exploring Gluten Contamination Thresholds Provoking Symptoms

Although NCGS patients often report feeling better when they avoid gluten entirely, it is unknown if small gluten exposure equivalent to those found in products with a gluten-free label causes adverse effects. To improve health-related quality of life, dose-response challenges that pinpoint each person's unique thresholds for recurrent symptoms may be a better way to guide personal tolerance limits. It is also essential to consider allowing less restrictive diets without compromising long-term intestinal healing [25].

### 1.2.5. Clarifying the Utility of Concurrent Grain Elimination Diets

According to anecdotal evidence, patients with NCGS respond better when they avoid grains other than gluten [26]. However, few controlled studies have evaluated the therapeutic relevance of extending exclusion diets to incorporate other cereals like rice, corn, and oats, often substituted to compensate nutritionally. Quantifying any additive clinical benefits, assessing specific symptomatic versus serological manifestations, and weighing this against potentially more significant dietary deficiencies from overly restrictive regimens constitute a vital evidence gap requiring clarification [26].

### 1.2.6. Identifying Psych-Emotional Profiles and Risk Factors

Appreciating bidirectional brain-gut interactions in functional gastrointestinal conditions characterizing psychological and psychosocial factors influencing susceptibility, clinical presentation, and management outcomes seems imperative when addressing a disorder like NCGS with conceivable mind-body origins [27]. Whether unique personality traits, previous adverse life events, concurrent mood disorders, perceived stress levels, somatic amplification tendencies, coping reserves, and social support networks act as predisposing and/or perpetuating etiologic elements merits investigation through mixed-methods research incorporating quantitative psychometric instruments and qualitative interview techniques [27]. This could enable targeting multimodal lifestyle-based interventions towards high-risk groups.

### 1.2.7. Investigating Diet Over Restrictiveness and Nutritional Deficiencies

Considering inherently limited food choices following a

gluten-free diet, patients eliminating additional items risk developing nutritional deficiencies over time. Nonetheless, more information is needed on the adequate intake and serum levels of essential nutrients such as iron, calcium, fiber, and B vitamins in NCGS. A directed supplementation program based on surveillance testing and monitoring for warning indicators such as amenorrhea, osteopenia, and anemia may prevent developing deficiencies [28]. To balance removing perceived triggers against guaranteeing adequate consumption of macronutrients and micronutrients, tailored liberalization efforts could benefit from evaluating any correlations between the degree of deprivation and sustained symptom control.

### 1.2.8. Establishing Best Practices for Multidisciplinary Care Coordination

For recently diagnosed patients, navigating the gluten-free transition can be pretty challenging as they have to deal with emotional responses, change long-standing eating habits, acquire specialty ingredients, and cook new foods, all while being on the lookout for unintentional exposures [29]. Accommodation burdens can be reduced by receiving multimodal support from peer networks, specialized dietitians, lifestyle coaching, mind-body modalities, and follow-up gastrointestinal care [29]. Examining the best infrastructure models that combine the dietary, psychological, and social domains under one cohesive system could improve patient empowerment by implementing evidence-based practices adaptable to different treatment environments.

### 1.2.9. Assessing the Usefulness of Complementary Wellness Approaches

Some NCGS patients may benefit even more from holistic practices like mindfulness, meditation, yoga, acupuncture, massage therapy, and meeting new dietary restrictions [30]. Further research should be done on integrating these complementary wellness interventions, either alone or combined, as supplemental methods to support traditional elimination diets and symptom-targeted pharmaceutical treatments. Clinicians can provide more personalized lifestyle modification counseling if they can quantify the contributions made to enhancing health status, quality of life, long-term adherence, and underlying pathophysiological mechanisms related to psychoneuroimmunology pathways [30,31].

## 2. Conclusion

In conclusion, gluten sensitivity is a nutritional, immunological, and microbiological condition that modern medicine has underappreciated, misdiagnosed, and undertreated when viewed through mind-body interactions. In the face of this enormous challenge, the presence of compassionate practitioners who embrace therapeutic optimism is just as significant as the continued investigation of mechanistic processes and evidence-guided protocols through empirical clinical trials and laboratory-based essential science endeavors. The most important links between bench research and bedside best practices are understanding the characteristically erratic manifestations

in the domains of gastrointestinal, cognitive, psychological, and quality of life and creating supportive environments that promote long-term self-efficacy and self-empowerment. Gluten sensitivity identically beckons medical professionals towards philosophical humility as recently acknowledged lifestyle-limiting allergies to foods illuminate a profound grace that awaits discovery through ancient recuperation art requirements balancing simplistic and comprehensive lenses. This is similar to how the essence of personalized care requires sitting first in patients' shoes to grasp embodied experiences.

## References

1. Biesiekierski, J. R. (2017). What is gluten? *Journal of gastroenterology and hepatology*, 32, 78-81.
2. Igbinedion, S. O., Ansari, J., Vasikaran, A., Gavins, F. N., Jordan, P., et al (2017). Non-celiac gluten sensitivity: All wheat attack is not celiac. *World journal of gastroenterology*, 23(40), 7201.
3. Hills, R. D., Pontefract, B. A., Mishcon, H. R., Black, C. A., Sutton, S. C., et al (2019). Gut microbiome: profound implications for diet and disease. *Nutrients*, 11(7), 1613.
4. Borroto-Escuela, D. O., Ambrogini, P., Chruścicka, B., Lindskog, M., Crespo-Ramirez, M., et al (2021). The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: a historical perspective and future prospects. *International journal of molecular sciences*, 22(4), 1927.
5. DiGiacomo, D. V., Tennyson, C. A., Green, P. H., Demmer, R. T. (2013). Prevalence of gluten-free diet adherence among individuals without celiac disease in the USA: results from the Continuous National Health and Nutrition Examination Survey 2009–2010. *Scandinavian journal of gastroenterology*, 48(8), 921-925.
6. Elli, L., Tomba, C., Branchi, F., Roncoroni, L., Lombardo, V., et al (2016). Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge. *Nutrients*, 8(2), 84.
7. McAllister, B. P., Williams, E., Clarke, K. (2019). A comprehensive review of celiac disease/gluten-sensitive enteropathies. *Clinical reviews in allergy immunology*, 57, 226-243.
8. Calabriso, N., Scoditti, E., Massaro, M., Maffia, M., Chieppa, M., et al (2022). Non-celiac gluten sensitivity and protective role of dietary polyphenols. *Nutrients*, 14(13), 2679.
9. Roszkowska, A., Pawlicka, M., Mroczek, A., Bałabuszek, K., Nieradko-Iwanicka, B. et al (2019). Non-celiac gluten sensitivity: a review. *Medicina*, 55(6), 222.
10. Fasano, A. (2012). Leaky gut and autoimmune diseases. *Clinical reviews in allergy immunology*, 42, 71-78.
11. Junker, Y., Zeissig, S., Kim, S. J., Barisani, D., Wieser, H., et al (2012). Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. *Journal of Experimental Medicine*, 209(13), 2395-2408.
12. De Palma, G., Nadal, I., Collado, M. C., Sanz, Y. (2009). Effects of a gluten-free diet on gut microbiota and

- immune function in healthy adult human subjects. *British journal of nutrition*, 102(8), 1154-1160.
13. Konturek, P. C., Brzozowski, T., Konturek, S. J. (2011). Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol*, 62(6), 591-9.
  14. Catassi, C., Elli, L., Bonaz, B., Bouma, G., Carroccio, A., et al (2015). Diagnosis of non-celiac gluten sensitivity (NCGS): the Salerno experts' criteria. *Nutrients*, 7(6), 4966-4977.
  15. Papandreou, C., Moré, M., Bellamine, A. (2020). Trimethylamine N-oxide in relation to cardiometabolic health—cause or effect? *Nutrients*, 12(5), 1330.
  16. Ballester-Fernández, C., Varela-Moreiras, G., Úbeda, N., Alonso-Aperte, E. (2021). Nutritional status in Spanish adults with celiac disease following a long-term gluten-free diet is similar to non-celiac. *Nutrients*, 13(5), 1626.
  17. Kushwah, B. S., Maheshwari, P. (2020). A Study on Shift of HRM Practices to E-HRM Practices. *Index/AZwH \$ \_oUH \$ m*.
  18. Casellas, F., Rodrigo, L., Vivancos, J. L., Riestra, S., Pantiga, C., et al (2008). Factors that impact health-related quality of life in adults with celiac disease: a multicenter study. *World journal of gastroenterology: WJG*, 14(1), 46.
  19. George, J. B. E., Aideyan, B., Yates, K., Voorhees, K. N., O'Flynn, J., et al (2022). Gluten-induced neurocognitive impairment: results of a nationwide study. *Journal of Clinical Gastroenterology*, 56(7), 584-591.
  20. Matsumura, Y., Kitabatake, M., Kayano, S. I., Ito, T. (2023). Dietary phenolic compounds: their health benefits and association with the gut microbiota. *Antioxidants*, 12(4), 880.
  21. Saha, B. K., Milman, N. T. (2021). Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. *Clinical Rheumatology*, 40(7), 2547-2557.
  22. Martinez, M., Gómez-Cabellos, S., Giménez, M. J., Barro, F., Diaz, I., et al (2019). Plant proteases: from key enzymes in germination to allies for fighting human gluten-related disorders. *Frontiers in plant science*, 10, 721.
  23. de Lourdes Moreno, M., Segura, V., Ruiz-Carnicer, Á., Nájara, A. M., Comino, I., et al (2021). Oral enzyme strategy in celiac disease. In *Biotechnological Strategies for the Treatment of Gluten Intolerance* (pp. 201-220). *Academic Press*.
  24. Qiu, J., Wilkens, C., Barrett, K., Meyer, A. S. (2020). Microbial enzymes catalyzing keratin degradation: Classification, structure, function. *Biotechnology advances*, 44, 107607.
  25. Rangel Paniz, G., Lebow, J., Sim, L., Lacy, B. E., Farraye, F. A., et al (2022). Eating disorders: diagnosis and management considerations for the IBD practice. *Inflammatory Bowel Diseases*, 28(6), 936-946.
  26. Duncanson, K., Burns, G., Pryor, J., Keely, S., Talley, N. J. et al (2021). Mechanisms of food-induced symptom induction and dietary management in functional dyspepsia. *Nutrients*, 13(4), 1109.
  27. Wahid, S. S. (2021). Understanding the Mental Health of Young Men Living in an Urban Slum of Bangladesh. *The George Washington University*.
  28. Fiot, E., Alauze, B., Donadille, B., Samara-Boustani, D., Houang, M., et al (2022). Turner syndrome: French national diagnosis and care protocol (NDCP; national diagnosis and care protocol). *Orphanet Journal of Rare Diseases*, 17(Suppl 1), 261.
  29. Walker, R. J., Walker, R. E., Mosley-Johnson, E., Egede, L. E. (2021). Insights about interventions to address food insecurity in adults with type 2 diabetes: Valuable lessons from the stories of African Americans living in the inner city. *Patient education and counseling*, 104(11), 2785-2790.
  30. Schuck, H. I. (2017). *Dr. Herb's Solutions to the Root Causes of Stress*. Author House.
  31. Cabanillas, B. (2020). Gluten-related disorders: Celiac disease, wheat allergy, and nonceliac gluten sensitivity. *Critical reviews in food science and nutrition*, 60(15), 2606-2621.